Input On Premarket Approval Process Sought By FDA At Aug. 18 Meeting
This article was originally published in The Gray Sheet
The premarket approval program within FDA's Center for Devices and Radiological Health will be among a host of subjects for which FDA is seeking recommendations at its Aug. 18 "stakeholders" meeting.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.